AstraZeneca/$AZN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About AstraZeneca
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
Ticker
$AZN
Sector
Primary listing
Employees
94,300
Headquarters
Website
AstraZeneca Metrics
BasicAdvanced
$263B
15.92
$5.31
0.15
$1.54
1.20%
Price and volume
Market cap
$263B
Beta
0.15
52-week high
$86.57
52-week low
$61.24
Average daily volume
5.2M
Dividend rate
$1.54
Financial strength
Current ratio
0.863
Quick ratio
0.664
Long term debt to equity
57.992
Total debt to equity
73.508
Dividend payout ratio (TTM)
59.51%
Interest coverage (TTM)
10.77%
Profitability
EBITDA (TTM)
19,128
Gross margin (TTM)
82.26%
Net profit margin (TTM)
14.68%
Operating margin (TTM)
25.40%
Effective tax rate (TTM)
17.17%
Revenue per employee (TTM)
$600,000
Management effectiveness
Return on assets (TTM)
8.28%
Return on equity (TTM)
19.67%
Valuation
Price to earnings (TTM)
15.92
Price to revenue (TTM)
2.319
Price to book
4.41
Price to tangible book (TTM)
-13.67
Price to free cash flow (TTM)
15.736
Free cash flow yield (TTM)
6.35%
Free cash flow per share (TTM)
5.371
Dividend yield (TTM)
1.82%
Forward dividend yield
1.20%
Growth
Revenue change (TTM)
15.00%
Earnings per share change (TTM)
28.86%
3-year revenue growth (CAGR)
8.66%
10-year revenue growth (CAGR)
8.20%
3-year earnings per share growth (CAGR)
86.70%
10-year earnings per share growth (CAGR)
18.97%
3-year dividend per share growth (CAGR)
2.58%
10-year dividend per share growth (CAGR)
1.12%
What the Analysts think about AstraZeneca
Analyst ratings (Buy, Hold, Sell) for AstraZeneca stock.
Bulls say / Bears say
AstraZeneca’s experimental hypertension drug baxdrostat met its primary endpoint in a late-stage trial for treatment-resistant hypertension, paving the way for a regulatory filing by end-2025 and targeting over $5 billion in peak annual sales (Reuters)
The $555 million licensing agreement with Algen Biotechnologies secures exclusive rights to AI-driven CRISPR gene-editing platforms, bolstering AstraZeneca’s cell and gene therapy pipeline and supporting its $80 billion revenue goal by 2030 (Reuters)
AstraZeneca topped second-quarter profit expectations with an 11% revenue increase to $14.46 billion and core EPS of $2.17—surpassing forecasts thanks to strong oncology and U.S. sales—reinforcing its growth trajectory (Reuters)
AstraZeneca delayed trial results for its lung-cancer candidate AVANZAR until 2026, deferring anticipated revenue contributions and slowing its oncology pipeline rollout (Reuters)
A UK court invalidated AstraZeneca’s Forxiga patent in April and upheld that decision on appeal in July 2025, exposing its SGLT2 franchise (approximately 15% of product revenue) to immediate generic competition in the UK (SEC filing)
Alexion, an AstraZeneca subsidiary, faces a U.S. class-action lawsuit alleging anticompetitive patent manipulations on its blockbuster drug Soliris, with over $2 billion in claimed damages that could materialize if the suit succeeds (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2025.
AstraZeneca Financial Performance
Revenues and expenses
AstraZeneca Earnings Performance
Company profitability
AstraZeneca News
AllArticlesVideos
AstraZeneca's drug pricing deal with Trump far from clear result, say analysts
Proactive Investors2 days ago
AstraZeneca furthers ambition to redefine cancer care with first data from four major pivotal trials at ESMO
Business Wire2 days ago
AstraZeneca agrees to offer US discounts in exchange for no tariffs
Proactive Investors2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for AstraZeneca stock?
AstraZeneca (AZN) has a market cap of $263B as of October 15, 2025.
What is the P/E ratio for AstraZeneca stock?
The price to earnings (P/E) ratio for AstraZeneca (AZN) stock is 15.92 as of October 15, 2025.
Does AstraZeneca stock pay dividends?
Yes, the AstraZeneca (AZN) stock pays dividends to shareholders. As of October 15, 2025, the dividend rate is $1.535 and the yield is 1.2%. AstraZeneca has a payout ratio of 59.51% on a trailing twelve-month basis.
When is the next AstraZeneca dividend payment date?
The next AstraZeneca (AZN) dividend payment date is unconfirmed.
What is the beta indicator for AstraZeneca?
AstraZeneca (AZN) has a beta rating of 0.15. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.